tPA's biological role is limited to degrading the surface of the clot.

With TSci’s regimen, once this occurs, the small amount of tPA used is rapidly cleared from the blood flow. HisproUK, TSci's compound, exclusively targets the now degraded clot and dissolves it.

Should there be no degraded clot, as in the case of stroke mimics or a hemorrhagic stroke, HisproUK will remain safely in its inactive pro enzymatic form before being cleared in minutes from the blood flow. 

TSci's thrombolytic regimen could therefore be given safely on simple suspicion of an ischemic stroke, as soon as possible after stroke onset.